1,491 Shares in Amgen Inc. $AMGN Acquired by Optimize Financial Inc

Optimize Financial Inc acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 1,491 shares of the medical research company’s stock, valued at approximately $421,000.

Other hedge funds also recently modified their holdings of the company. Legacy Investment Solutions LLC bought a new stake in Amgen in the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen during the second quarter worth approximately $32,000. Howard Hughes Medical Institute acquired a new stake in shares of Amgen in the second quarter valued at approximately $32,000. Quaker Wealth Management LLC raised its position in shares of Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC bought a new stake in shares of Amgen in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat and company guidance lifted — Amgen reported Q4 EPS and revenue above Street estimates and issued FY‑2026 EPS and revenue guidance that came in around expectations while signaling continued product-volume growth; this is the primary catalyst pushing the stock higher. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
• Positive Sentiment: Goldman Sachs raised its price target to $415 and kept a Buy rating — a high-profile upward revision that signals confidence in Amgen’s growth runway and likely supports further buying interest. Goldman Sachs adjusts price target on Amgen to $415 from $403, maintains Buy
• Positive Sentiment: Portfolio & pipeline momentum — coverage notes highlight double‑digit revenue and EPS growth for 2025 and faster uptake of new Amgen products (including obesity assets) that underpin the company’s guidance and longer‑term upside. Amgen posts double-digit revenue and EPS growth for 2025
• Positive Sentiment: Obesity program and late‑stage data in focus — investors are increasingly oriented toward MariTide/MariTide‑related obesity studies and other pipeline catalysts that could materially add revenue, helping explain enthusiastic flows. AMGN’s Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
• Positive Sentiment: Technical/institutional signal — the stock is trading near 52‑week highs and commentary suggests heavy institutional buying, reinforcing momentum into today’s session. Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $350 but kept a Neutral rating — PT higher but rating unchanged, so limited directional push from this call. Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald
• Neutral Sentiment: Morgan Stanley nudged its target to $309 but kept an Equal‑Weight rating — the firm raised its view slightly but still implies downside vs. the current price, so the call is not uniformly bullish. Morgan Stanley raises price target on Amgen to $309 from $304, keeps Equal-Weight
• Negative Sentiment: Analysts flag execution/legacy‑product risks — some coverage (Citi and others) notes legacy product erosion and execution risks that could temper upside if new products don’t scale as expected. That is the key watch‑out for investors despite today’s positive headlines. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks

Amgen Stock Performance

Shares of Amgen stock opened at $366.22 on Thursday. The company’s 50 day moving average price is $333.19 and its two-hundred day moving average price is $310.44. The firm has a market capitalization of $197.20 billion, a P/E ratio of 25.74, a P/E/G ratio of 2.98 and a beta of 0.46. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $368.75. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 152.71% and a net margin of 20.98%.Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 in the last 90 days. Corporate insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on AMGN shares. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Guggenheim increased their price objective on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Leerink Partners boosted their target price on shares of Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday. Wells Fargo & Company upped their price target on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Finally, UBS Group increased their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $347.65.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.